EGFR and non-small cell lung carcinoma: A phase III trial of dacomitinib versus gefitinib as first-line therapy for patients with EGFR mutation-positive NSCLC demonstrated improved progression-free survival: 14.7 versus 9.2 months [146], and a 4-year update on the status of patients in this trial showed overall survival benefit from first-line treatment with dacomitinib in comparison with gefitinib: OS was 34.1 months with dacomitinib versus 27.0 months with gefitinib [147].